A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the ...
A recent article posted to the Research Square* preprint server illustrated that early intervention with azelastine nasal spray therapy might lower the severe acute respiratory syndrome coronavirus 2 ...
Glenmark pharma’s nasal spray administered to adult Covid-19 patients showed reduction of the viral load by 94% within 24 hours and by 99% in 48 hours, according to the phase 3 trial results published ...
Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research & Development Corp. has announced the launch of FabiSpray, a nitric oxide nasal spray (NONS), for the treatment ...
Glenmark Pharmaceuticals and its strategic partner SaNOtize Research and Development Corp published their peer-reviewed Phase 3 clinical trials of their Nitric Oxide Nasal Spray (NONS) in the medical ...
The second wave of the coronavirus disease (Covid-19) continues to wreak havoc across the world. Several countries have expanded their vaccination drives and are administering doses to children and ...
Even as the global medical community continues to look for ways to cure and prevent Covid-19, a Mumbai-based pharmaceutical company has tested a nasal spray that has shown to effectively cure Covid-19 ...
Covid Nasal Spray: A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of ...
A nasal spray administered in high-risk adult Covid-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results